$4.31 +0.25 (6.16%) Cyclacel Pharmaceuticals Inc - NASDAQ

Dec. 5, 2016 | 04:00 PM

Quotes

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Last Trade: 4.31
Trade Time: Dec 05 04:00 PM Eastern Daylight Time
Change: +0.25 (6.16%)
Prev Close: 4.06
Open: 4.03
Bid: 4.19
Ask: 4.28
  1. No results found.
  1. Benzinga's Weekend M&A Chatter

    Benzinga | Nov. 29, 2015 | 19:44PM EST
  2. Benzinga's Top Initiations

    Benzinga | Oct. 16, 2015 | 08:27AM EST
  3. Cyclacel Announces Presentation of Molecular Rationale for Clinical Development of CYC065 CDK Inhibitor in Leukemias, Lymphomas

    Benzinga | Sep. 17, 2015 | 06:04AM EST
  4. Cyclacel Announces First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease,

    Benzinga | Jul. 2, 2015 | 06:04AM EST
  5. Wilbur Ross Buys Two New Stakes in First Quarter

    GuruFocus | Jun. 15, 2015 | 15:59PM EST
  6. Morning Market Losers

    Benzinga | Dec. 16, 2014 | 09:57AM EST
  7. Cyclacel Pharma Reports CYC065 CDK Inhibitor Shows Terapeutic Potential in Acute Leukemias with MLL Rearrangements

    Benzinga | Sep. 18, 2014 | 06:02AM EST
  8. Events Scheduled for Week of Jun 23rd to Jun 27th, 2014

    Benzinga | Jun. 23, 2014 | 17:25PM EST
  9. Cyclacel Pharmaceuticals, Inc. Announces Closing of $10 Million Underwritten Offering

    Benzinga | Apr. 9, 2014 | 15:06PM EST
  10. Benzinga's Top #PreMarket Losers

    Benzinga | Apr. 4, 2014 | 07:22AM EST
  11. Earnings Scheduled For March 25, 2014

    Benzinga | Mar. 25, 2014 | 04:08AM EST
  12. Cyclacel Reports Positive Phase 2 Data of Sapacitabine for MDS at ASH

    Benzinga | Dec. 9, 2013 | 07:07AM EST
  13. Cyclacel Pharma Announces Data Safety Monitoring Board Recommends Continuation of SEAMLESS Study of Sapacitabine in AML

    Benzinga | Nov. 25, 2013 | 07:18AM EST
  14. Morning Market Losers

    Benzinga | Sep. 23, 2013 | 09:14AM EST
  15. Benzinga's Top Pre-Market Gainers

    Benzinga | Sep. 20, 2013 | 07:10AM EST
Trading Center